| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 1099 |
| 1 | OXALIPLATIN | 299 |
| 2 | FLUOROURACIL | 275 |
| 3 | FLUOROURACIL CREAM, 0.5% | 274 |
| 4 | PACLITAXEL | 273 |
| 5 | CAPECITABINE | 240 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 239 |
| 7 | CARBOPLATIN | 226 |
| 8 | TOCILIZUMAB | 206 |
| 9 | PEMBROLIZUMAB | 204 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBUPROFEN LYSINE | 29 | 0.0510 |
| 1 | RAMUCIRUMAB | 78 | 0.0123 |
| 2 | BEVACIZUMAB | 1099 | 0.0088 |
| 3 | 3% SODIUM CHLORIDE | 1 | 0.0088 |
| 4 | LEVOLEUCOVORIN INJECTION | 26 | 0.0085 |
| 5 | DIMETICONE | 2 | 0.0071 |
| 6 | LEVOLEUCOVORIN | 27 | 0.0071 |
| 7 | CARTEOLOL HYDROCHLORIDE | 2 | 0.0060 |
| 8 | DEXTROSE AND SODIUM CHLORIDE | 1 | 0.0060 |
| 9 | ZIV-AFLIBERCEPT | 7 | 0.0054 |
| # | Drug class | Count |
|---|---|---|
| 0 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1117 |
| 1 | Platinum-based Drug [EPC] | 623 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 523 |
| 3 | Corticosteroid [EPC] | 507 |
| 4 | Microtubule Inhibitor [EPC] | 329 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 287 |
| 6 | Interleukin-6 Receptor Antagonist [EPC] | 215 |
| 7 | Proton Pump Inhibitor [EPC] | 146 |
| 8 | Alkylating Drug [EPC] | 140 |
| 9 | Kinase Inhibitor [EPC] | 120 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 78 | 0.0123 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1117 | 0.0060 |
| 2 | Interferon gamma Blocker [EPC] | 1 | 0.0042 |
| 3 | Platinum-based Drug [EPC] | 623 | 0.0023 |
| 4 | Microtubule Inhibitor [EPC] | 329 | 0.0020 |
| 5 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 3 | 0.0020 |
| 6 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 7 | CD30-directed Immunoconjugate [EPC] | 20 | 0.0019 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 523 | 0.0019 |
| 9 | Interleukin-6 Receptor Antagonist [EPC] | 215 | 0.0016 |